CRANBURY, N.J., Nov. 13, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, announced today its Vice President of Research, Dr. Paul Bingham, will participate in a pre-conference workshop panel discussion at the Target TME Conference on Monday, November 18 th , 9:00 a.m. – 12:00 p.m. ET, in Boston, MA.
The workshop, entitled, "Targeting Mitochondria and Cancer Metabolism: Opportunities for Drug Discovery," will feature Dr. Bingham as part of a small panel that aims to educate those attending with a comprehensive overview of the latest research and clinical investigations in tumor metabolism and highlight the therapeutic opportunities available. The workshop will provide attendees with an update on some of the leading projects in this space, including recently initiated clinical trials evaluating Cornerstone's lead therapeutic candidate, CPI-613.
Dr. Bingham commented, "The pre-conference workshop will be a tremendous opportunity to highlight recent developments in cancer metabolism and further solidify Cornerstone as a leader in this space. There are many therapeutic areas within the tumor microenvironment that are currently being explored, and this panel discussion will provide great insight into identifying certain pathways of interest that will provide novel cancer metabolism targets. Selection to speak on this panel acknowledges credibility for the scientific breakthroughs that our team at Cornerstone has been able to generate with regard to novel cancer metabolism therapeutics."
CPI-613 is a first-in-class agent that induces cancer-specific inhibition of pyruvate dehydrogenase (PDH) and alpha ketoglutarate dehydrogenase (KGDH), key mitochondrial enzymes involved in fueling cancer cell metabolism. Disruption of PDH and KGDH function cuts off the tumor's energy supply and starves the cancer cell, leading to cancer cell death. CPI-613 is currently being evaluated in Phase I, I/II and II human clinical trials in solid tumors and hematological malignancies.
CPI-613 is the lead drug candidate from Cornerstone's proprietary Altered Energy Metabolism Directed (AEMD) platform. Cornerstone's AEMD drug platform disrupts biochemical alterations in the conversion of glucose to energy that occur in many types of cancer cells. These essential bioenergetic differences are linked to critical pathways, particularly those that support cancer cell growth and development.
About Cornerstone Pharmaceuticals
Cornerstone Pharmaceuticals, Inc. is a privately held company that is committed to changing the way cancer is treated through the discovery and development of innovative therapies capitalizing on the unique metabolic processes of cancer cells. The company's founding members, management and scientific advisory team include pre-eminent scientists focused on cancer cell metabolism, cancer research and drug development. The company's unique approach to targeting cancer metabolism has led to the discovery of first-in-class drugs with the potential to transform the way cancer is treated. www.cornerstonepharma.com .
This release contains forward-looking statements. These statements relate to future events or each company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Investor Contact: Stephanie Carrington/ David Burke The Ruth Group (646) 536 -7017/ 7009 Media Contacts: Aaron Estrada / Amy Wheeler The Ruth Group (646) 536 -7028 / 7025
